Clinical Trials Browser

Astrocytoma, Craniopharyngioma, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroma, Acoustic, Oligodendroglioma, Pinealoma, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Glioma, Subependymal, Gliosarcoma

NCT00112736 2015-06-15

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Phase 1/2 Completed

69 enrolled 12 charts

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00004146 2015-05-08

Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM

Phase 2 Completed

55 enrolled 10 charts

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT00036894 2015-04-30

CC-5013 in Treating Patients With Recurrent Glioma

Phase 1 Completed

CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Meningioma, Oligodendroglioma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Gliosarcoma

NCT00074243 2015-04-30

CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas

Phase 1 Completed

CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00019058 2015-04-29

Radiation Therapy in Treating Patients With Glioblastoma

Phase 1 Completed

34 enrolled

CNSSarcoma

Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00019071 2015-04-29

Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma

Phase 1 Completed

CNSSarcoma

Astrocytoma, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01122888 2015-04-28

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

Phase 1 Terminated

41 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Clinical Trials

Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Sunitinib in Sarcomas of the Central Nervous System

Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

GW572016 to Treat Recurrent Malignant Brain Tumors

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas

Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma

Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme

Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme

Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma

Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma

O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy

Pazopanib in Treating Patients With Recurrent Glioblastoma

FR901228 in Treating Patients With Recurrent High-Grade Gliomas

A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas

Sunitinib in Treating Patients With Recurrent Malignant Gliomas

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM

CC-5013 in Treating Patients With Recurrent Glioma

CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas

Radiation Therapy in Treating Patients With Glioblastoma

Chemotherapy Followed by Radiation Therapy in Treating Patients With Malignant Glioma

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme